A breast cancer vaccine currently in clinical trials has been haulted due to a serious side effect announced  on Tuesday by Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc..

“The suspension affects the Phase 3 clinical program for Stimuvax, including the START and INSPIRE trials in non-small cell lung cancer (NSCLC) and the STRIDE trial in breast cancer. Further recruitment of patients into all trials actively recruiting patients and ongoing treatment with Stimuvax in these trials are suspended.”

Read more: http://www.biospace.com/news_story.aspx?NewsEntityId=174661 KL